Green J A, Errington R D, Nash J R, Coe M A, Warenius H M
Department of Radiation Oncology, Clatterbridge Hospital, Wirral, Merseyside, U.K.
Cancer Chemother Pharmacol. 1989;24(5):326-8. doi: 10.1007/BF00304767.
31 patients with intermediate and high-grade non-Hodgkin lymphomas were treated by a six-drug alternating regime comprising four cycles of 200 mg/m2 i.v. methotrexate on days 8, 15, 28 and 35, 50 mg/m2 i.v. Adriamycin on day 1, 40 mg/m2 oral prednisolone on days 1-7 and 21-27, 120 mg/m2 i.v. etoposide on days 21-23, 600 mg/m2 i.v. cyclophosphamide on day 21 and 1.4 mg/m2 i.v. vincristine on day 1 (MAPECO). In all, 3 patients had stage I disease, 12 stage II, 6 stage III and 10 stage IV. Of 28 evaluable patients, 19 were complete responders (68%) and 9 were partial responders (32%); at 2 years, the actuarial relapse-free survival of the 19 patients achieving complete remission is 80%, and 5 patients remain in complete remission at 3 years. This is a preliminary report of an effective intensive regime with acceptable toxicity.
31例中高级别非霍奇金淋巴瘤患者接受了一种六药交替方案治疗，该方案包括四个周期，具体用药如下：第8、15、28和35天静脉注射甲氨蝶呤200mg/m²；第1天静脉注射阿霉素50mg/m²；第1 - 7天和21 - 27天口服泼尼松龙40mg/m²；第21 - 23天静脉注射依托泊苷120mg/m²；第21天静脉注射环磷酰胺600mg/m²；第1天静脉注射长春新碱1.4mg/m²（MAPECO方案）。总共有3例患者为Ⅰ期疾病，12例为Ⅱ期，6例为Ⅲ期，10例为Ⅳ期。在28例可评估患者中，19例为完全缓解者（68%），9例为部分缓解者（32%）；2年时，19例达到完全缓解患者的无病生存率为80%，3年时5例患者仍处于完全缓解状态。这是关于一种有效且毒性可接受的强化方案的初步报告。
